The economic burden of disease progressionin extra-pulmonary neuroendocrinecarcinoma (epNEC): A multimodal database analysis

AMCP-N 2026

Oct 26, 2026
Oncology
Presentation

N. Vijayvergia, N. Liu, E. Liu, A. Curran, E. Scherrer, K. Vrieze, A. Christensen, S. Ijioma, C. Gay

Background
Extra-pulmonary neuroendocrine carcinomas(epNEC) are rare and aggressive neoplasms with an incidenceof ~1 per 100,000 individuals, characterized by rapid progres-sion and poor prognosis. A recent analysis demonstratedthat costs increase up to 58% from first-line to second-linetherapy; however, the economic burden of disease progres-sion remains uncharacterized.OBJECTIVE: To describe the cost of progression in patientstreated for epNEC by comparing progressors to non-progressors.METHODS: A retrospective, longitudinal study of patientsdiagnosed with epNEC (August 2012-March 2025) was con-ducted using the Tempus de-identified multimodal datasetlinked to Komodo Healthcare Map claims data. Costs wereassessed as a per-patient per-month (PPPM) rate using stand-ardized 2025 Medicare Fee Schedule reference costs. Theindex date was defined as the earliest of first progression orinitiation of subsequent line of therapy. For non-progressors,the index date was randomly assigned based on the progres-sor cohort’s time-to-progression distribution. Inverseprobability of treatment weighting (IPTW) was used to bal-ance age, payer type, and Charlson Comorbidity Index (CCI)between progression cohorts. Cost ratios were estimatedusing a gamma regression model.RESULTS: Among 105 patients (81 progressors; 24 non-progressors), the median age was 61 years, 42% were female,87% had gastrointestinal primary tumors, and 66% hadstage IV disease at initial diagnosis. Payers included commercial(52%), Medicare (32%), and Medicaid (13%), with a median CCIof 2.69. After IPTW balancing, progressors comparedto non-progressors had a cost ratio of 2.69 (p < 0.001) timeshigher mean total all-cause ($7,703 vs $2,860, p < 0.001),2.61 (p = 0.006) times higher mean total cancer-specific($4,969 vs $1,902, p = 0.011), 2.20 (p = 0.015) times higher meanall-cause outpatient ($3,949 vs $1,795, p = 0.016), and 2.99(p = 0.020) times higher mean all-cause pharmacy ($310 vs$104, p = 0.044) costs PPPM. Additionally, progressors hadsignificantly higher all-cause hospitalization ($2,836 vs $525,p = 0.017), cancer-specific hospitalization ($2,174 vs $322,p = 0.040), and other cancer-specific ($257 vs $7, p = 0.034)costs PPPM.CONCLUSIONS: Disease progression in epNEC imposes a sub-stantial economic burden, with progressors consistentlyexhibiting more than twice the total all-cause, total cancer-specific, all-cause outpatient, and all-cause pharmacy costscompared with non–progressors, underscoring the need fortherapies that delay or prevent progression and improveoutcomes.